Role of the α1blocker doxazosin in alcoholism: a proof-of-concept randomized controlled trial: Doxazosin and alcoholism
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Evidence suggests that the norepinephrine system represents an important treatment target for alcohol dependence (AD) and the α1 -blocker prazosin may reduce alcohol drinking in rodents and alcoholic patients. The α1 -blocker doxazosin demonstrates a more favorable pharmacokinetic profile than prazosin, but has never been studied for AD. A double-blind placebo-controlled randomized clinical trial was conducted in AD individuals seeking outpatient treatment. Doxazosin or matched placebo was titrated to 16 mg/day (or maximum tolerable dose). Drinks per week (DPW) and heavy drinking days (HDD) per week were the primary outcomes. Family history density of alcoholism (FHDA), severity of AD and gender were a priori moderators. Forty-one AD individuals were randomized, 30 (doxazosin = 15) completed the treatment phase and 28 (doxazosin = 14) also completed the follow-up. There were no significant differences between groups on DPW and HDD per week. With FHDA as a moderator, there were significant FHDA × medication interactions for both DPW (pcorrected = 0.001, d = 1.18) and HDD (pcorrected = 0.00009, d = 1.30). Post hoc analyses revealed that doxazosin significantly reduced alcohol drinking in AD patients with high FHDA and by contrast increased drinking in those with low FHDA. Doxazosin may be effective selectively in AD patients with high FHDA. This study provides preliminary evidence for personalized medicine using α1 -blockade to treat AD. However, confirmatory studies are required.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rhemtulla, M., Brosseau-Liard, P. É., & Savalei, V. (2012) · Psychological Methods · doi:10.1037/a0029315 · Cited by 2,816
A Role for Brain Stress Systems in Addiction
Koob, G. F. (2008) · Neuron · doi:10.1016/j.neuron.2008.06.012 · Cited by 1,056 · cited 6×
“Consistent with the literature (Trzaskowska et al. 1986; Koob 2008; Walker et al. 2008), α1-blockade represents a mechanism of action more likely to be effective in patients with more biologically based AD and/or higher severity of dependence.”
BackgroundResultInfluentialProfile of Mood States: the factors and their physiological correlates.
POLLOCK, V., CHO, D. W., REKER, D., & VOLAVKA, J. (1979) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-197910000-00004 · Cited by 143 · cited 4×
“There were significant main effects of FHDA on craving scales (total OCDS: F1,34 = 6.25, P = 0.017; ODS: F1,35 = 6.97, P = 0.012; CDS F1,34 = 5.45, P = 0.026), anxiety (HAMA: F1,34 = 5.13, P = 0.030) and mood (POMS-TA: F1,32 = 7.44 P = 0.010), but not PSS (P > 0.05).”
MethodInfluential
Cited by
Alcohol, stress, and glucocorticoids: From risk to dependence and relapse in alcohol use disorders
Blaine, S. K., & Sinha, R. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.01.037 · Cited by 257
Influence of stress associated with chronic alcohol exposure on drinking
Becker, H. C. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.04.028 · Cited by 191
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder
Burnette, E. M., Nieto, S. J., Grodin, E. N., Meredith, L. R., Hurley, B., Miotto, K., Gillis, A. J., & Ray, L. A. (2022) · Drugs · doi:10.1007/s40265-021-01670-3 · Cited by 169
“, drinks per week, heavy-drinking days) [208].”
Noradrenergic targets for the treatment of alcohol use disorder
Haass-Koffler, C. L., Swift, R. M., & Leggio, L. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4843-6 · Cited by 117
Self-citationDysregulation of brain stress systems mediates compulsive alcohol drinking
Tunstall, B. J., Carmack, S. A., Koob, G. F., & Vendruscolo, L. F. (2017) · Current Opinion in Behavioral Sciences · doi:10.1016/j.cobeha.2016.10.006 · Cited by 55
Metadata
- Authors
- Kenna, G. A., Haass-Koffler, C. L., Zywiak, W. H., Edwards, S. M., Brickley, M. B., Swift, R. M., & Leggio, L.
- Venue
- Addiction Biology
- Publisher
- Wiley
- Published
- 2015-06-02
- Volume
- 21
- Issue
- 4
- Pages
- 904-914
- ISSN
- 1355-6215 (ISSN-L)
- OpenAlex
- W1805631454
- Cited by
- 67
- References
- 3
- FWCI
- 4.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Role of the α1blocker doxazosin in alcoholism: a proof-of-concept randomized controlled trial: Doxazosin and alcoholism. https://app.cochat.ai/papers/10.1111/adb.12275
- The paper
- Kenna, G. A., Haass-Koffler, C. L., Zywiak, W. H., Edwards, S. M., Brickley, M. B., Swift, R. M., & Leggio, L. (2016). Role of the α1blocker doxazosin in alcoholism: a proof-of-concept randomized controlled trial: Doxazosin and alcoholism. Addiction Biology. https://doi.org/10.1111/adb.12275
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.